Results 161 to 170 of about 2,475,393 (270)

Use of Dipeptidyl-Peptidase IV Inhibitors and Bullous Pemphigoid [PDF]

Dermatology, 2017
Schaffer, Clara, Buclin, Thierry, Jornayvaz, François, Cazzaniga, Simone, Borradori, Luca, Gilliet, Michel, Feldmeyer, Laurence   +6 more
openaire   +3 more sources

Real‐World Effectiveness and Safety of Finerenone in People With Type 2 Diabetes and Chronic Kidney Disease: A Spanish Multicentre Retrospective Observational Study (MEDFINE‐RWD)

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9461-9472, October 2026.
ABSTRACT Aim Although finerenone has shown efficacy in randomized trials, evidence from routine clinical practice remains limited. We aimed to assess the real‐world effectiveness and safety of finerenone in people with type 2 diabetes (PWT2D) and chronic kidney disease (CKD), with a particular focus on residual cardiorenal risk as reflected by changes ...
Oscar Moreno‐Pérez, Antonio Tejera‐Muñoz, Patricia Tomás‐Gómez, Federico Vázquez‐San Miguel, Virginia Soria‐Utrilla, Ada María Roldán‐Sánchez, Maya Sánchez‐Baya, Jersy Cárdenas‐Salas, Blanca Timón‐Vázquez, Juan J. Gorgojo‐Martínez, Ines Modrego‐Pardo, Irea Fernández‐Xove, Jose Carlos Fernández‐García, Rebeca Reyes‐García   +13 more
wiley   +1 more source

Time to Insulin Initiation Among Patients With Type 2 Diabetes Treated With Second‐Line Antidiabetic Drugs

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9655-9667, October 2026.
ABSTRACT Objective To examine the effect of second‐line treatments (insulin secretagogues, thiazolidinediones, glucagon‐like peptide‐1 (GLP‐1) receptor agonists, dipeptidyl peptidase‐4 (DPP‐4) inhibitors or sodium‐glucose co‐transporter 2 (SGLT‐2) inhibitors) on time to insulin initiation among patients with type 2 diabetes.
Ya‐Hui Yu, Qi Zhang, Estefania Zapata‐Bravo, Robert W. Platt, Pauline Reynier, Oriana H. Y. Yu, Kristian B. Filion   +6 more
wiley   +1 more source

Efficacy and Safety of the Utilization of Dipeptidyl Peptidase IV Inhibitors in Diabetic Patients with Chronic Kidney Disease: A Meta-Analysis of Randomized Clinical Trials. [PDF]

Diabetes Metab Syndr Obes
Mahzari MM, Alqirnas MQ, Alhamadh MS, Alrasheed F, Alhabeeb AY, Al Madani W, Aldera H.   +6 more
europepmc   +1 more source

The Role of Neuropeptide Y in Dental Pulp: Balancing Neurogenic Inflammation and Pain Modulation

International Endodontic Journal, Volume 59, Issue 10, Page 2028-2045, October 2026.
ABSTRACT Background Dental pulp is a densely innervated, low‐compliance tissue in which neurogenic inflammation can rapidly escalate into oedema, raised intrapulpal pressure, microvascular compromise, and pain. While Substance P (SP) and Calcitonin gene‐related peptide (CGRP) are well‐established drivers of pulp vasodilation, the Neuroopeptide Y (NPY ...
Javier Caviedes‐Bucheli, Esteban Ulate, Hugo‐Roberto Munoz, Nestor Ríos‐Osorio   +3 more
wiley   +1 more source

Beyond Simple Mimicry: Next‐Generation Geometric Architectures and Future Paradigms in Small‐Molecule and Macrocyclic Peptidomimetics

Angewandte Chemie, Volume 138, Issue 40, 28 September 2026.
Peptide‐to‐Small Molecule Paradigm: Peptidomimetics have evolved from simple mimicry toward drug‐like scaffolds supported by increasing clinical successes. This Perspective highlights the geometric design principles—linear repetition, convergent fusion, and cyclization—defining the next‐generation peptidomimetic architectures capable of targeting ...
Jesang Lee, Sumin Son, Jeong Yeon Yoo, Ji Hyae Lee, Meehyun Chun, Seung Bum Park   +5 more
wiley   +2 more sources

USP30 inhibits wound healing in diabetic foot ulcers by promoting TRAF6‐induced ferroptosis and angiogenesis inhibition

Journal of Diabetes Investigation, Volume 17, Issue 10, Page 1708-1725, October 2026.
High glucose upregulates USP30 in HUVECs, which deubiquitinates and stabilizes TRAF6. Stabilized TRAF6 suppresses GPX4 and SLC7A11, increases ROS/MDA/lipid peroxidation, and activates ferroptosis and apoptosis, leading to impaired angiogenesis and delayed wound healing.
Jingjing Yuan, Shuang Sui, Zhenghua Yang, Kaiwen Zhang, Qiang Hu   +4 more
wiley   +1 more source

The miR‐145‐5p/NRF2/SLC7A11 axis regulates ferroptosis‐mediated renal tubular epithelial cell injury in diabetic nephropathy

Journal of Diabetes Investigation, Volume 17, Issue 10, Page 1667-1685, October 2026.
Suppression of miR‐145‐5p alleviates DN‐associated renal tissue damage by inhibiting NRF2/SLC7A11‐mediated ferroptosis of RTECs. ABSTRACT Purpose This study aimed to investigate the molecular mechanism by which the miR‐145‐5p/NRF2/SLC7A11 axis regulates ferroptosis‐mediated renal tubular epithelial cell (RTEC) injury in diabetic nephropathy (DN ...
Ganlin Wu, Yu Fang, Meirong Xu, Zuopeng Lu, Yu Cao, Yana Gao   +5 more
wiley   +1 more source

Association of glycation gap with hypoglycemia CGM indices, diabetic complications, and quality of life in Japanese type 2 diabetes patients

Journal of Diabetes Investigation, Volume 17, Issue 10, Page 1794-1806, October 2026.
The difference between HbA1c and estimated A1c (eA1c) was defined as the GGap. The strong association of high GGap with CGM‐based hypoglycemic indices in type 2 diabetes is evident. The large GGap values, relying solely on HbA1c values during treatment, may increase the risk of hypoglycemia in patients with T2DM.
Satomi Sonoda, Yosuke Okada, Tomoya Mita, Keiichi Torimoto, Kenichi Tanaka, Fumiya Sato, Naoto Katakami, Hidenori Yoshii, Keiko Nishida, Shingo Nakayamada, Ryota Ishii, Masahiko Gosho, Iichiro Shimomura, Hirotaka Watada   +13 more
wiley   +1 more source

Effects of age, sex, and renal function on bowel movement‐improving effects of Bifidobacterium bifidum G9‐1 on constipation in patients with type 2 diabetes mellitus and chronic kidney disease: A prespecified subgroup analysis of the BIRDIE study

Journal of Diabetes Investigation, Volume 17, Issue 10, Page 1759-1769, October 2026.
This prespecified subgroup analysis of the BIRDIE study demonstrated that Bifidobacterium bifidum G9‐1 improved stool consistency, bowel movement, and quality of life in patients with type 2 diabetes mellitus, chronic kidney disease, and specifically in age ≥ 65 years, male, and those with eGFR ≥60 mL/min/1.73 m2.
Fuki Ikeda, Junko Sato, Hidenori Yoshii, Hiroaki Satoh, Hirotsugu Uzawa, Daisuke Sugimoto, Reina Muto, Yuya Nishida, Hirotaka Watada   +8 more
wiley   +1 more source